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Autoimmune hematological diseases (AHDs) may occur after allogeneic hematopoietic stem cell trans-
plantation (HSCT), but reports on these complications in large cohorts of pediatric patients are lacking. Be-
tween 1998 and 2011, 1574 consecutive children underwent allogeneic HSCT in 9 Italian centers. Thirty-three
children (2.1%) developed AHDs: 15 autoimmune hemolytic anemia (45%), 10 immune thrombocytopenia
(30%), 5 Evans’ syndrome (15%), 2 pure red cell aplasia (6%), and 1 immune neutropenia (3%). The 10-year
cumulative incidence of AHDs was 2.5% (95% confidence interval, 1.7 to 3.6). In a multivariate analysis, the
use of alternative donor and nonmalignant disease was statistically associated with AHDs. Most patients with
AHDs (64%) did not respond to steroids. Sustained complete remission was achieved in 87% of cases with the
anti-CD20 monoclonal antibody (rituximab). Four patients (9%) (1 autoimmune hemolytic anemia, 1 Evans’
syndrome, 2 immune thrombocytopenia) died at a median of 87 days after AHD diagnosis as a direct or
indirect consequence of their disorder. Our data suggest that AHDs are a relatively rare complication
occurring after HSCT that usually respond to treatment with rituximab.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION suggest that immune dysregulation or incomplete immune
Autoimmune disorders, including autoimmune hemato-
logical diseases (AHDs), have been reported to occur more
frequently than other autoimmune complications after both
autologous and allogeneic hematopoietic stem cell trans-
plantation (HSCT) [1-7]. AHDsmay involve a single lineage of
blood cells, such as autoimmune hemolytic anemia (AIHA),
immune thrombocytopenia (ITP), autoimmune neutropenia
(AIN), or 2 and/or 3 lineages (such as Evans’ syndrome in
which AIHA is associated with ITP and/or AIN). The causes of
AHDs after HSCT have been the object of several studies, but
the association of these complications with graft-versus-host
disease (GVHD), T cell depletion, HSCT from an unrelated
donor, and the use of serotherapy, in particular alemtuzumab,edgments on page 278.
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13.11.014reconstitution may be the pathogenetic mechanism leading
to the development of these complications [1-5].
The management of post-transplantation AHDs is com-
plex, and the response to immunosuppressive therapies is
often either incomplete or transient. There are reports on the
incidence of AIHA cases in pediatric HSCT recipients [3,7],
and an analysis of autoimmune diseases occurring after cord
blood transplantation has recently been published [6], but
the description of post-transplantation AHDs in a large
cohort of children is lacking. The aims of this Italian retro-
spective, observational, multicenter pediatric study are to
report the cumulative incidence, to analyze the risk factors,
and to describe the clinical features, treatment, and outcome
of AHDs occurring in a series of children who underwent
allogeneic HSCT.METHODS
This study involved all consecutive allogeneic HSCT recipients reported
to the Italian Association of Paediatric Haematology and Oncology (AIEOP)-
HSCT Registry and treated between 1998 and December 2011 at any AIEOPTransplantation.
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6 months were collected and analyzed. The AIEOP centers that agreed to
participate in the study were asked to identify patients affected by AHD and
to answer a specific questionnaire, including queries addressing clinical
features of AHDs, laboratory characteristics, therapies used, and outcome.
Data concerning demographics, type of primary diagnosis, date and type of
transplantation, conditioning regimen, type of stem cell source, and GVHD
(maximum grade, duration, and treatment) were retrieved from the AIEOP-
HSCT Registry for each study subject. HSCT was classified as (1) matched
related donor, including patients who received geno-/phenotypically HLA
identical or with a single locus mismatch, and (2) alternative donor,
including patients who received HSCT from an unrelated volunteer or from
an HLA partially matched/haploidentical related donor.
We analyzed the response to first- and second-line treatment and
categorized it as (1) complete response (CR) in cases of normalization of the
clinical signs and laboratory tests for AHD, (2) partial response when an
improvement in clinical symptoms or laboratory analyses and/or steroid
dependence was observed despite the presence of autoantibodies, or (3)
nonresponse when the clinical signs/symptoms and laboratory findings
were either unchanged or worsened despite therapy.
This retrospective study was approved by the AIEOP-HSCT board. The
procedures we followed were in accordance with our institution’s ethical
standards and with the Helsinki Declaration. As per Italian guidelines, no
other specific informed consent was required other than a general agree-
ment to clinical and laboratory data collection for scientific purposes
expressed at the time of transplantation.
Statistical Analysis
Patients’ data were collected using patient-oriented forms, filled in by
the physician in charge at each center and sent to the AIEOP Operations
Office in Bologna where data were stored in an electronic database (AIEOP-
HSCT Registry) for quality control and statistical analysis by Venus, a
facilities-integrated software system running on an IBM mainframe at the
Italian Inter-University Computing Centre (CINECA).
Quantitative variables were reported as median and range, whereas
categorical variables were expressed as absolute number and percentage.
The incidence of AHDwas defined as the probability of having AHD at time t,
death in remission or disease relapse considered the competing event [8].
AHD was calculated as a cumulative incidence curve to adjust the estimate
for competing risks [9,10]. All results were expressed as 10-year cumulative
incidences and 95% confidence intervals (CIs) [8].
The following variables were included in the univariate analysis of fac-
tors predicting the development of AHD: patient gender, median age at
diagnosis, type of original disease (malignant versus nonmalignant), median
age at HSCT, type of conditioning regimen (total body irradiationebased
versus chemotherapy-based), type of stem cell source, type of GVHD pro-
phylaxis, and acute and chronic GVHD occurrence. Logistic regression was
used to perform the multivariate analysis, and the model included all vari-
ables with P < .05 in univariate analysis. The chi-square test was used to
compare percentage differences. All P values were 2-sided, and P < .05 wereFigure 1. Cumulative inconsidered statistically significant. P > .1 was reported as not significant
(NS), whereas P between .05 and .1 were reported in detail.
Statistical analysis was performed using Number Cruncher Statistical
System 2007 (Kaysville, UT) and R 2.5.0 software package (http://www.R-
project.org) [11-13]. Data were analyzed as of December 15, 2012.
RESULTS
Nine of 20 AIEOP centers performing allogeneic HSCT
(45%) agreed to participate in this study. Overall, they per-
formed 41% (n ¼ 1574) of the 3830 transplants reported to
the AIEOP-HSCT Registry during the study period. These
centers provided the data concerning the childrenwho were
eligible for this study, and among them a total of 33 AHDs
(2.1%) were reported. The median follow-up after trans-
plantation of AHD patients was 43.5 months (range, 6 to
163.6). AHD was diagnosed after a first transplant in 29 pa-
tients, whereas in 4 cases it occurred after a second HSCT
performed for either relapse (n ¼ 2) or graft failure (n ¼ 2).
Cumulative Incidence
The cumulative incidence of AHDs was 1.53% (95% CI, 1.02
to 2.30) 1 year after HSCT; it was 2.05% (95% CI, 1.44 to 2.92)
2 years after HSCT, 2.13% (95% CI, 1.50 to 3.02) 3 and 5 years
after transplantation, and 2.50% (95% CI, 1.74 to 3.57) 10 years
after HSCT. The cumulative incidence was significantly
different between groups of patients who received matched
related (.74%) and alternative donor (3.62%) stem cells
(P < .001) (Figure 1).
Risk Factors
The main characteristics of patients who did or did not
develop AHDs are reported in Table 1. Univariate analysis
(Table 1) showed no significant correlation between the
development of AHD and patient gender, type of condition-
ing regimen (total body irradiation versus chemotherapy
based), type of GVHD prophylaxis, or acute and chronic
GVHD occurrence. On the contrary, the following factors
were found to be significantly associated with an increased
risk of AHD: younger age at HSCT (3.1 years [range, .7 to 18.9]
for patients developing AHD versus 8.8 years [range, .3 to 22]
for patients not developing these disorders; P ¼ .0005),
transplantation from an alternative donor (P¼ .004), primarycidence of AHDs.
Table 1
Clinical Risk Factors for AHD after Allogeneic HSCT and Univariate Analysis
Patients
with AHD
Patients
without AHD
P
Gender, n (%)
Male 16 (48) 922 (60) .1887
Female 17 (52) 619 (40)
Median age at diagnosis,
yr (range)
2.2 (.1-16.6) 6.1 (.1-20) .04
Type of underlying disease, n (%)
Malignant 11 (34) 1208 (78) <.0001
Nonmalignant 22 (66) 333 (22)
Median age at HSCT, yr (range) 3.1 (.7-18.9) 8.8 (.3-22) .0005
Type of HSCT, n (%)
Alternative donor 29 (88) 978 (63) .004
Matched related donor 4 (12) 563 (37)
Type of conditioning
regimen, n (%)
TBI based 6 (18) 654 (58) .015
Chemotherapy based 27 (81) 887 (42)
Source of stem cell, n (%)
Bone marrow 18 (55) 1154 (73) .003
PBSC 5 (15) 237 (15)
Cord blood 10 (30) 183 (12)
Type of GVHD prophylaxis, n (%)
CSA þATG  MTXs 28 (85) 617 (40) .01
CSA  MTXs 3 (9) 805 (51)
T depletion  other 1 (3) 115 (7)
Other or none 1 (3) 4 (2)
Acute GVHD, n (%)
No 10 (30) 456 (30) .794
Yes 23 (69) 947 (61)
Grades I-II 17 (74) 740 (78)
Grades III-IV 6 (26) 207 (22)
Unknown 0 138 (9)
Chronic GVHD, n (%)
No 18 (55) 894 (58) .042
Yes 13 (39) 357 (23)
Not applicable/unknown 2 (6) 290 (19)
Limited 5 (39) 200 (56)
Extensive 8 (61) 157 (44)
Total, n (%) 33 (2.1) 1541 (97.9)
BM indicates bone marrow; PBSC, peripheral blood stem cells; TBI, total
body irradiation; ATG, antithymocyte globulin; CSA, cyclosporine; MTXs,
short course of methotrexate.
Table 2
Multivariate Analysis of Risk Factors Associated with the Occurrence of AHD
Risk Factors Odds Ratio 95% CI P
Chronic GVHD
Extensive vs. absent 2.29 .85-6.18 .102
Limited vs. absent 1.39 .48-3.97 .544
Age at HSCT (per yr) .94 .86-1.02 .138
Stem cell source
CB vs. BM 1.76 .69-4.49 .235
PBSC vs. BM 1.08 .34-3.48 .894
Diagnosis
Nonmalignant vs. malignant 6.87 2.51-8.78 .00017
TBI: yes vs. no 1.36 .43-4.37 .601
Donor
MUD vs. MFD 3.73 1.23-1.27 .019
PMFD vs. MFD 2.14 .35-3.21 .412
BM indicates bone marrow; CB, cord blood; PBSC, peripheral blood stem
cells; TBI, total body irradiation; MUD, matched unrelated donor; MFD,
matched family donor; PMFD, partially matched family donor.
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of cord blood as stem cell source (P ¼ .003). In multivariate
analysis, primary diagnosis of a nonmalignant disease
(P ¼ .00017) and the use of an alternative donor (P ¼ .019)
remained factors significantly associated with the develop-
ment of AHD (Table 2).Clinical Characteristics and Treatments
Table 3 reports the transplant characteristics of patients
experiencing AHD. Table 4 shows details on type of AHD
treatment (first- and second-line treatment) and on final
outcome. First- and second-line treatment included steroids
(methylprednisolone or other type of steroids) at dosages
ranging from 1 to 40 mg/kg, intravenous immunoglobulin
(IVIG) administered from 400 mg/kg/day to 1 g/kg/day for
several courses, and rituximab (RTX) given at 375 mg/m2
weekly for 2 to 6 courses.
AIHA as a single manifestation of AHD was diagnosed in
15 children (46%) at a median of 5.2 months (range, 1.3 to
100.9) after HSCT. The 10-year cumulative incidence of AIHA
was 1.5% (95% CI, .95 to 2.41). The median hemoglobin level
at AIHA diagnosis was 7.4 g/dL (range, 4.5 to 9.4); 11 of 15
children received a median of 3 RBC transfusions (range, 1 to
8). Six children (40%) affected by AIHA achieved CR afterfirst-line therapy including methylprednisolone alone
(n ¼ 3) or associated with IVIG (n ¼ 2) and RTX (n ¼ 1),
whereas 7 of 8 children who did not respond to first-line
treatment obtained CR after a median of 1.8 months (range,
1 to 3) after RTX was administered as second- or third-line
therapy (Table 4).
Ten patients presented ITP (30%) at a median of
40.2 months (range, 2.5 to 101.68) after HSCT. The 10-year
cumulative incidence of ITP was .9% (95% CI, .05 to 1.80).
The median number of platelets at the time of ITP diagnosis
was 16,500/mL (range, 3000 to 48,000), and antibodies
against platelets were found to be positive in 6 of 8 evaluated
patients (75%). Four childrenwith ITP achieved CR after first-
line treatment including IVIG (n ¼ 3) and methylpredniso-
lone (n ¼ 1). Of the remaining 6 patients, 2 were responsive
to RTX and 1 to an infusion of allogeneic CD34, whereas 2
died of transplant-related complications and 1 of relapse of
the underlying disease. Four children developed an infection
before or during ITP, and the origin was viral (cytomegalo-
virus) in 2 cases and mycotic (1 candida, 1 aspergillus) in
2 cases.
Five children developed Evans’ syndrome (15%) (4 AIHAþ
ITP, 1 AIHAþ ITPþAIN) at a median of 9.2months after HSCT
(range, 2.4 to 24.4). Two patients with AIHA þ ITP obtained
CR 3 and 6 months after RTX as first- or second-line treat-
ment, and the third achieved CR after steroids administered
as first-line treatment. One child died of multiple organ
failure 6 months after Evans’ syndrome diagnosis despite
several immunosuppressive therapies (steroids, IVIG, 6 doses
of RTX, vincristine, cyclophosphamide, plasma exchange,
splenectomy, alemtuzumab, and rapamycin) (Table 4). The
child with Evans’ syndrome characterized by AIHA þ ITP þ
AIN was affected by type 1 mucopolysaccharidosis and
developed autoimmune pancytopenia in the context of
chronic extensive GVHD 23 months after a second unrelated
donor bone marrow HSCT had to be performed due to pri-
mary graft failure of the unrelated donor cord blood HSCT.
Although CR of AIHA and ITP was obtained after 4 doses of
RTX, AIN persisted in the contest of chronic GVHD treated
with dexamethasone, 2 courses of monoclonal antibodies
against anti-CD25, rapamycin, and finally a CD34þ positively
selected boost of peripheral blood stem cells from the orig-
inal donor. Fifteen months after the diagnosis of Evans’
syndrome, hematological values returned within normal
ranges even though low direct antiglobulin test positivity
persisted.
Table 3
Characteristics of Patients with AHD, Transplantation, Procedures, Outcome, and Development of AHD
Patient No. Primary Disease Sex Yr of HSCT Age at HSCT (yr/mo) Conditioning Regimen Donor Cell Origin GVHD Prophylaxis aGVHD Maximum Grade cGVHD Survival Status AHD
1 HLH M 1998 3 mo Bus,VP16,CY AD CB ATG,CSA,MPD Absent Absent 5.6 mo (D) AIHA
2 MPS1 F 1999 1.5 yr Bus,CY AD BM ATG,CSA,MPD Absent Absent 145 mo (A) AIHA
3 Langh. His M 2002 2.1 yr Bus,Vp16,CY AD CB ATG,CSA,MPD I Absent 114 mo (A) AIHA
4 ALL M 2003 11.8 yr TBI,TT,CY AD BM ATG,CSA,MTXs II Limited 103 mo (A) AIHA
5 HLH M 2005 1.7 yr Bus,TT,Fluda AD BM ATG,CSA,MTXs Absent Absent 80.1 mo (A) AIHA
6 MPS1 F 2006 1.5 yr Bus,CY AD CB ATG,CSA,MPD II Extensive 69.1 mo (A) AIHA
7 AML F 2007 9 mo Bus,CY,L-PAM AD BM ATG,CSA,MTXs I Absent 53 mo (A) AIHA
8 Fanconi A F 2008 5.2 yr Fluda,CY,ATG AD CB CSA,MPD II Extensive 44.7 mo (A) AIHA
9 C. Anemia M 2008 4.4 yr TT, Treo,Fluda AD PBSC ATG,CSA,MTXs Absent Absent 36.4 mo (A) AIHA
10 AML M 2009 17.2 yr Bus,CY,L-PAM AD BM ATG,CSA,MTXs II Limited 25.6 mo (A) AIHA
11 ALL F 2010 3.2 yr TBI,TT,CY AD BM ATG,CSA,MTXs I Absent 20.1 mo (A) AIHA
12 ALL F 2010 1.9 yr Bus,TT,CY AD PBSC ATG,CSA,MTXs I Absent 18.2 mo AIHA
13 SAA M 2010 6.5 yr Fluda,CY,ATG AD BM CSA,MTXs Absent Absent 17.7 mo (A) AIHA
14 SAA M 2010 8.4 yr Fluda,CY,ATG AD BM CSA,MTXs II Absent 14.5 mo (A) AIHA
15 ALL M 2011 2.9 yr TT,Treo,Fluda AD BM ATG,CSA,MTXs II Absent 4.7 mo (A) AIHA
16 SAA F 2003 12.1 yr Fluda,CY,ATG AD BM CSAþMTXs II Extensive 102 mo (A) ITP
17 Fanconi A F 2005 9.25 yr Fluda,CY,400TBI,ATG AD BM CSA III Extensive 72.5 mo (A) ITP
18 Osteopetrosis M 2007 7 mo Bus,CY,TT AD CB ATG,CSA,MPD II Limited 52 mo (A) ITP
19 Fanconi A F 2008 6.2 yr Fluda,CY,ATG RD BM CSA,MTXs IV Extensive 42.3 mo (A) ITP
20 SCID M 2008 9 mo Bus,CY AD CB ATG,CSA,MPD Absent Absent 42.9 mo (A) ITP
21 SAA F 2008 2.2 yr Fluda,CY,ATG RD* BM CSA,MTXs Absent Absent 38.5 mo A) ITP
22 NB F 2009 12,6 yr TT,L-PAM ADy PBSC ATG,CSA,MTXs IV Extensive 6.45 mo (D) ITP
23 MPS 1 F 2009 9 mo Bus,CY AD CB ATG,CSA,MPD II Limited 24.2 mo (A) ITP
24 ALL F 2010 19 yr TBI,TT,CY RD BM CSA III NE 2.5 mo (D) ITP
25 AML F 2011 11.4 yr Bus,TT,Fluda ADz BM ATG,Basil,CSA,MMF Absent Absent 5.7 mo (D) ITP
26 MPS1 F 2001 1.1 yr Bus,CY AD BM ATG,CSA,MPD Absent Absent 131 mo (A) Evans
27 SCID M 2007 10 d No CR AD BM No GVHD proph. III Absent 57.5 mo (A) Evans
28 ALL M 2008 16.5 yr TBI,TT,CY AD PBSC ATG,CSA,MTXs IV Extensive 38.4 mo (A) Evans
29 MPS1 M 2010 2.7 yr Bus,CY AD CB ATG,CSA,MPD II Absent 9 mo (D) Evans
30 MPS1 F 2010 3.7 yr TT,Treo,Fluda ADx BM Campath,Tac,MTXs II Extensive 15.5 mo (A) Evans
31 ThalassemiaM M 1998 7.7 yr Bus,CY RD BM CSA,ATG Absent Absent 164 mo (D) PRCA
32 WAS M 2010 9 mo Treo,Fluda AD BM ATG,CSA Absent Absent 14.5 mo (A) PRCA
33 ALL F 2007 16.8 yr TBI,TT,CY AD PBSC ATG,CSA,MTXs I Limited 53.9 mo (A) AIN
M indicates male; F, female; HLH, hemophagocytic lymphohistiocytosis; ThalassemiaM, thalassemiamajor; MPS1, mucopolysaccaridosis type 1; Langh His, Langherans cell histiocytosis; ALL, acute lymphoblastic leukemia; AML,
acute myeloid leukemia; SAA, severe aplastic anemia; Fanconi A, Fanconi anemia; SCID, severe combined immunodeficiency disease; WAS, Wiskott-Aldrich syndrome; C. Anemia, congenital anemia; NB, neuroblastoma; Proph,
prophylaxis; Bus, busulfan; CY, cyclophosphamide; AD, alternative donor; Fluda, fludarabine; L-PAM, melphalan; TT, thiotepa; TBI, total body irradiation; Treo, treosulphan; VP16, etoposide; ATG, antithymocyte globulin; UD,
unrelated donor; RD, related donor; PMRD, partially matched related donor; Haplo, haploidentical donor; BM, bone marrow; PBSC, peripheral blood stem cells; CB, cord blood; CSA, cyclosporine A; MPD, methylprednisolone;
MTXs, short course of methotrexate; Tac, tacrolimus; Basil, basiliximab; MMF,mycophenolatemofetil; GF, graft failure; A, alive; D, dead; NE, not assessable; AHD, autoimmune disease; mo(s), month(s); d(s), day(s); yr(s), year(s);
Infect, infections; aGVHD, acute GVHD; cGVHD, chronic GVHD; AIHA, autoimmune hemolytic anemia; Evans, Evans’ syndrome; ITP, immune trombocytopenia; PRCA, pure red cell aplasia.
* Patient received a second HSCT due to primary graft failure after a first RD HSCT conditioned with Flu, Cy, ATG (GVHD prophylaxis with MTXþCSA).
y Patient received a second HSCT due to a relapse that occurred 2 yr after the first autologous HSCT (conditioned with BusþLPAM).
z Patient received a second HSCT due to a relapse that occurred 1 yr after a first CB HSCT conditioned with Bus, Cy, LPAM (GVHD prophylaxis with ATG, CSA, MPD).
x Patient received a second HSCT due to graft failure that occurred after a first cord blood HSCT conditioned with Bus, CY (GVHD prophylaxis with ATG, CSA, MPD).
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Table 4
Characteristics of Patients with AHD, Treatments, Responses, and Outcome
Patient No. AHD Mo from HSCT Age at AHD
(yr/mo)
Infect aGVHD
cGVHD
First-Line Therapy Response
(Time)
Second- to Third-Line
Therapy
Response
(Time)
Survival
Status
Cause of Death Follow-up of
AHD (days, mo)
1 AIHA 3.3 6 mo NO NO MPD: 5 mg/kgþ IVIG: 400 mg/kg  5 CR (1 mo) Dead Traumatic
Hemothorax
10 days
2 AIHA 4.7 2 NO NO MPD (40 mg/kg) PR IvIg/ RTX (3) CR (1 mo) Alive 140 mo
3 AIHA 4.3 2.5 EBV NO MPD (2 mg/kg) PR RTX (4) CR (1 mo) Alive 109 mo
4 AIHA 100.9 20.6 NO NO MPD (2 mg/kg) PR Rapa PR Alive 3.5 mo
5 AIHA 13.6 2.8 NO NO MPD (2 mg/kg) þ IVIG (400 mg/kg  5) PR RTX (4) CR (1 mo) Alive 66 mo
6 AIHA 5.9 2 NO Extes MPD (2 mg/kg) PR RTX (2) CR (1 mo) Alive 64 mo
7 AIHA 9.4 1.7 NO NO MPD (2 mg/kg) CR (1 mo) Alive 44 mo
8 AIHA 8.1 6 CMV NO IVIG (800 mg/kg  1) NR RTX (2) CR (3 mo) Alive 37 mo
9 AIHA 10.1 5.2 NO NO MPD (5 mg/kg) CR (1 mo) Alive 26 mo
10 AIHA 1.3 17.3 BK/EBV II RTX (2) CR (3 mo) Alive 25 mo
11 AIHA 4.9 3.6 CMV NO MPD(10 mg/kg) NR RTX (5) CR (3 mo) Alive 15.1 mo
12 AIHA 18.1 3.4 CMV NO MPD (2 mg/kg) þ IVIG (800 mg/kg  2) CR (1 mo) Alive 1 mo
13 AIHA 7.3 7.1 NO NO MPD (5 mg/kg) PR Alive 10.4 mo
14 AIHA 5 8.9 Adeno NO MPD (1 mg/kg) CR (1 mo) Alive 10 mo
15 AIHA 3.8 3.3 EBV NO MPD (2 mg/kg) PR RTX (3) CR (3 mo) Alive 4.7 mo
16 ITP 68.8 17.9 NO NO IVIG (400 mg/kg  2) CR (1 mo) Alive 33 mo
17 ITP 7.3 9.8 CMV Exten IVIG (1 g/kg) CR (7 days) Alive 65 mo
18 ITP 9.2 1.5 NO NO MPD (30 mg/kg) þ
IVIG (800 mg/kg  3)
PR RTX (4) CR (1 mo) Alive 43 mo
19 ITP 12.8 7.3 NO Lim PDN (.5 mg/kg) þ IVIG (800 mg/kg  3) PR CD34þ for PT CR (2 mo) Alive 30 mo
20 ITP 6.7 1.5 NO NO Beta (.4 mg/kg) þ IVIG (800 mg/kg  2) CR (15 days) Alive 35 mo
21 ITP 4.2 2.5 NO NO PDN (1 mg/kg) þ IVIG (800 mg/kg  2) NR RTX (3) CR (1 mo) Alive 34 mo
22 ITP 2.9 12.9 Asper IV DEXA (.9 mg/kg) þ IVIG (1 g/kg  1) NR Dead Hemorrhage,
Asper, cGVHD
3.5 mo
23 ITP 6.1 1.5 NO NO MPD (30 mg/kg) CR (1 mo) Alive 18.1 mo
24 ITP 1.7 19.9 CMV III MPD (1.5 mg/kg) NR Dead MOF, sepsis 23 days
25 ITP 2 11.5 Cand NO MPD (1 mg/kg) NR RTX (3) NR Dead Relapse 3.7 mo
26 Evans 21.8 2 V.Resp NO MPD (2 mg/kg) CR (1 mo) Alive 108 mo
27 Evans 24.4 2.8 NO NO IVIG (1 g/kg  6) NR RTX (3) CR (6 mo) Alive 33 mo
28 Evans 5.4 16.9 NO Exten RTX (4) CR (3 mo) Alive 33 mo
29 Evans 2.5 2.9 CMV NO MPD (2.4 mg/kg) þ IVIG (1 g/kg  14) NR RTX (6)/ VCR,CY,PX.. NR Dead MOF, anemia,
hemorrhage
6.5 mo
30 Evans 9.2 4.5 Pseud Exten MPD (4 mg/kg) þ IVIG (1 g/kg  2) NR RTX (4)/ Dexa,
Anti-CD25, CD34þ, Rapa
CR: AIHA/ITP
PR: AIN
Alive 15.5 mo
31 PRCA 2.3 8 NO NO EPO (150 UI/kg) PR MPD PR Alive 161 mo
32 PRCA 1.6 10 Klebs NO EPO (500 UI/kg) NR PDN (1 mg/kg) CR (1 mo) Alive 13 mo
33 AIN 14.3 18 NO NO PDN (1 mg/kg) þ IVIG (1 g/kg  7) CR (1 mo) Alive 40 mo
d(s) indicates day(s); Infect, infections; aGVHD, acute GVHD; cGVHD, chronic GVHD; Evans, Evans’ syndrome;M,male; F, female; VResp, respiratory virus; CMV, cytomegalovirus; EBV, Epstein-Barr virus; Adeno, adenovirus; Asp,
aspergillus; Pseud, pseudomonas; Klebs, klebsiella; Cand, candida; MPD, methylprednisolone; IVIG, intravenous immunoglobulin; EPO, erythropoietin; PDN, prednisone; Beta, betamethasone; DEXA, dexamethasone; PR, partial
response; NR, nonresponse; mo, month; RTX(n), number of doses of RTX; PT, poor take; Rapa, rapamycin; VCR, vincristine; CY, cyclophosphamide; PX, plasma exchange; CD34þ, infusion of allogeneic CD34þ cells; anti-CD25,
monoclonal antibody anti-CD25; MOF, multiple organ failure.
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with major donor-recipient ABO incompatibility 50 and
71 days after unrelated and related donor HSCT, respectively,
that were performed to treat nonmalignant disease. In both
patients, recombinant human erythropoietin (150 to 500 U/
kg/day, given weekly for 10 and 6 doses, respectively) was
unsuccessfully administered. Both patients received steroids,
and 1 achieved stable CR. In the second patient, complete
correction of PRCA was obtained after a second allogeneic
peripheral blood stem cell infusion preceded by cyclophos-
phamide and antithymocyte globulin.
One patient (3%) developed AIN 14.3 months after unre-
lated donor HSCT performed for acute lymphoblastic leuke-
mia. The search for indirect antibodies against neutrophils
was negative. CR was achieved 1 month after treatment with
steroids and IVIG (7 doses).
Rituximab Treatment
In our experience, 15 children received RTX as first- or
second-line therapy (8 AIHA,4 Evans’ syndrome,3 ITP). The
CR was obtained in 13 patients treated with RTX (87%) (100%
in AIHA group, 75% in Evans’ group, and 66% in ITP patients)
after a median of 60 days (range, 30 to 180) from start RTX
treatment.
Outcome
Twenty-eight of 33 patients with AHDs were alive at last
follow-up (85%). Five patients died after AHD diagnosis: 3
died without obtaining remission from AHD, and causes of
death were multiple organ failure in 1 Evans’ syndrome,
multiple organ failure and sepsis in 1 ITP, and chronic GVHD
and aspergillus in 1 ITP. Two patients died after obtaining CR
of AIHA and ITP, respectively: 1 of traumatic hemothorax
during the placement of a central venous catheter and 1 after
relapse of the underlying malignancy.
DISCUSSION
The literature reports the incidence and risk factors of
autoimmune-mediated hemolysis in adults [2,14,15] and
children [3], but there are only single case reports of other
AHDs (Evans’ syndrome, ITP, AIN, PRCA) in the pediatric age
group [7,16,17]. To the best of our knowledge, this is the first
report on AHDs occurring in a large population of consecu-
tive children who received any type of allogeneic HSCT. The
study is focused on the homogeneous group of organ-specific
alternative donors that most often occurred after HSCT.
Although the incidence of alternative donors after HSCT is
reported as the overall incidence of autoimmune manifes-
tations both hematological and nonhematological [6,18], it is
difficult to compare the incidence we observed with that of
other reports. Moreover, the incidence of AHD in our cohort
was lower than that reported in patients receiving cord blood
transplantations (41 of 726, 4.6%) [6] and higher than that
reported after autologous and allogeneic transplants for
autoimmune disease (6 of 363, 1.6%) [18]. The retrospective
nature of this study carries the risk of underestimating the
true incidence of AHDs (in particular of mild forms), and this
possibly explains the lower incidence of AHD we observed in
our population.
In our cohort of patients, nonmalignant underlying dis-
ease, transplantation from alternative donors, and cord blood
as a source of hematopoietic stem cells represented risk
factors statistically associated with AHDs in univariate anal-
ysis, whereas only the first 2 variables remained significant
in multivariate analysis. The importance of nonmalignantdisease as a risk factor for AIHAwas also reported by O’Brien
et al. [3] in a pediatric cohort and by Daikeler et al. [6] in the
EUROCORD experience, suggesting that a more competent
immune system before HSCT could predispose to the devel-
opment of autoimmune disorders after the allograft.
The higher frequency of AHD observed in children
transplanted from an alternative donor has also been re-
ported in other studies [3,14]. This observation could be
explained by the immunological dysregulation due to the use
of alemtuzumab or antithymocyte globulin administered
before unrelated donor HSCT [4], thus confirming previous
observations concerning the development of AIHA after
T celledepleted HSCT [2].
In our study, younger age at HSCT was found to be asso-
ciated with the risk of AHD, but this effect disappeared in
multivariate analysis. The association of AHD in younger pa-
tients is reported in some studies [3,6,7], but its pathogenesis
is not clear. Themost attractive hypothesis is reported byPage
et al. [7], who suggested a mechanism of interference
between post-transplant immunosuppressive therapies
(cyclosporine A, antithymocyte globulin) and the normal
immune ontogeny resulting in immune dysregulation.
The association between GVHD and autoimmunity is well
known [1], but the role of GVHD in post-transplant AHDs is
still under debate [3,6]. In our experience, few patients were
suffering from GVHD at the time of AHD (8 of 33 patients,
24%), and neither acute nor chronic GVHD was statistically
correlated with the development of AHD.
Infections may be an important trigger for autoimmune
events occurring after HSCT [5,14,19,20]. In our study, 33% of
patients with AHD had viral infection or reactivation before
or during the AHD. Fifty-four percent of these viral events
were represented by cytomegalovirus reactivations, thus
confirming that cytomegalovirus may contribute to the onset
of post-transplantation autoimmune complications [19].
Although the prognosis of patients with post-transplant
autoimmune diseases is variable and some spontaneous re-
missions are possible [21], the incidence of life-threatening
events and the resistance to first-line standard treatments
are most common in patients affected by AHDs [3,14-20].
Other drugs used on patients with post-transplantation
AHDs, either alone or in combination, include RTX [14,22-
24], IVIG [20,25], vincristin [26], splenectomy [27], and
other immunosuppressive treatments. The efficacy of RTX in
the treatment of AIHA [20-24,28,29], as well as the encour-
aging results reported in ITP [30] and PRCA [31], has led to an
increased and consolidated use of this monoclonal antibody
even in patients affected by post-transplantation AHDs
[3,6,20,22,24]. In our experience, steroid treatment alone
was unsuccessful in 64% of AHD pediatric recipients, thus
requiring the addition of other immunosuppressive thera-
pies. Our data support the use of RTX for AHDs occurring
after allogeneic HSCT (CR in 87% of patients treated with
RTX), confirming data reported in cord blood transplantation
recipients [6]. The long-term effect of RTX on B cell recon-
stitution of patients given an allograft remains to be further
investigated.
The effectiveness of IVIG administered alone or in associ-
ation with steroids for the treatment of post-transplantation
AHDs was reported only in single cases [20,25]. In the study
byHartert et al. [20], 5 patients (2 AIHA and3 ITP) treatedwith
IVIG during first-line therapy obtained CR, confirming the
reports in the literature stating that IVIG may be a good
treatment option for patients with post-HSCT AHD, in
particular for patients affected by ITP.
M. Faraci et al. / Biol Blood Marrow Transplant 20 (2014) 272e278278The efficacy of erythropoietin in the treatment of PRCA as
a late consequence of major ABO incompatibility was
demonstrated by some authors [30-33]. However, new
therapeutic strategies represented by the use of RTX [30] and
recently by bortezomib [34] have been proposed as a treat-
ment for PRCA. Regarding AIN, we confirmed that unlike
other AHDs, most patients with post-transplantation AIN
improved without any specific treatment [35] or after stan-
dard therapy with steroids and IVIG [36].
In conclusion, our retrospective pediatric study found
that (1) AHD is a relatively rare complication of the HSCT
course, with an observed 10-year cumulative incidence of
2.5% (95% CI, 1.7 to 3.6); (2) children with nonmalignant
diseases or receiving allograft from an alternative donor are
at especially high risk of developing AHD; (3) AIHA is the
most frequently reported AHD, followed by ITP, Evans’ syn-
drome, PRCA, and AIN; (4) RTX represents an efficacious
treatment for patients with steroid-refractory disease (87% of
CRs in treated patients); and (5) mortality due to AHD is
lower (9%) compared with other pediatric experiences [3,6],
suggesting that the new therapeutic approach has led to an
improvement in the prognosis of these patients.
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